Search Results

Your search for Richard M. Goldberg, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Thursday, July 17, 2014 11:05 AM

Poorer Progression-Free Survival and Overall Survival Seen in Youngest and Oldest Patients With Metastatic Colorectal Cancer

Lieu et al recently analyzed the effect of age on outcome in patients with metastatic colorectal cancer using the ARCAD (Aide et Recherche en Cancérologie Digestive) database. The findings, reported in the Journal of Clinical Oncology, indicate a U-shaped risk of death and death or...

colorectal cancer

By The ASCO Post Staff / Tuesday, June 4, 2013 1:38 PM

ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer

First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...

Apr

Today In Oncology

Search Results

Your search for Richard M. Goldberg, MD matches 2 pages

Poorer Progression-Free Survival and Overall Survival Seen in Youngest and Oldest Patients With Metastatic Colorectal Cancer

ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer